Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Corporate Reputation of Pharma Companies 2016-2017: Perspective of 63 HIV/AIDS Patient Groups - Research and Markets

Research and Markets
Posted on: 14 Aug 17

The "The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 63 HIV/AIDS Patient Groups" report has been added to Research and Markets' offering.

The HIV/AIDS results are drawn from the opinions of 63 patient groups specialising in HIV/AIDS, based in 35 countries, and, in turn, are derived from the global review of pharma's corporate reputation (conducted November 2016 to early-February 2017).

8 pharma companies are included in this 2016 HIV/AIDS therapy-area 'extra' analysis:

  • AbbVie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead
  • Janssen
  • Merck & Co
  • Roche
  • ViiV Healthcare

How pharma is assessed for corporate reputation

Industry-wide questions:

  • How the pharma industry's corporate reputation compares with that of other healthcare industries.
  • How the pharma industry's corporate reputation has changed over the past five years.
  • How good or bad the pharma industry is at various activities of relevance to patients and patient groups.

7 indicators for the corporate reputation of individual pharma companies:

  1. Patient centricity.
  2. Information for patients.
  3. Patient safety.
  4. Usefulness of products.
  5. Transparency.
  6. Integrity.
  7. Patient-group relationships(new for 2016).


  • In 2016, HIV/AIDS patient groups show higher regard for pharma than patient groups from most other therapy areas. 44% of HIV/AIDS patient groups thought that the pharma industry had an "Excellent" or "Good" corporate reputation in 2016 (just 38% of patient groups across all therapy areas thought the same).
  • HIV/AIDS patient groups ranked the generics drug industry as 1st among 8 healthcare-industry sectors for having a "Excellent" or "Good" corporate reputation in 2016. They ranked multinational pharma 4th.
  • HIV/AIDS patient groups were, on the whole, positive about many of the pharma industry's activities in 2016. Up to 76% stated that pharma was "Excellent" or "Good" at producing high-quality products of use to patients [see chart].
  • However, only 21% of HIV/AIDS patient groups stated that pharma was "Excellent" or "Good" at integrity (the figure among patient groups across all therapy areas was 35%, and 55% among haemophilia patient groups).


  • 63 HIV/AIDS patient groups participated in the 2016 study. They came from Africa, Asia, Europe, North America, and Central & Latin America. The majority of the HIV/AIDS patient groups worked with at least two-to-four pharma companies (and many worked with more than that). As the chart above shows, one HIV/AIDS patient group worked with as many as 12 pharma companies. Half of the 63 HIV/AIDS patient groups worked with four-to-seven pharma companies.
  • The company with which HIV/AIDS patient groups were most familiar was Gilead (83% of respondent HIV/AIDS patient groups were familiar with the company).


  • ViiV Healthcare ranked overall 1st in 2016 for corporate reputation among the 8 pharma companies, when judged by HIV/AIDS patient groups.
  • ViiV Healthcare also ranked 1st for six of the seven indicators of corporate reputation. The exception was the provision of high-quality products, for which HIV/AIDS patient groups ranked Gilead 1st.

For more information about this report visit

View source version on

Business Wire

Last updated on: 14/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.